about
Plant Polyphenols as Chemopreventive Agents for Lung CancerNRF2, a Key Regulator of Antioxidants with Two Faces towards CancerGlycosyltransferases and non-alcoholic fatty liver diseaseImpact of New Genomic Technologies on Understanding Adverse Drug ReactionsDiallyl Sulfide: Potential Use in Novel Therapeutic Interventions in Alcohol, Drugs, and Disease Mediated Cellular Toxicity by Targeting Cytochrome P450 2E1Regulation of the cytosolic sulfotransferases by nuclear receptorsDietary interactions with the bacterial sensing machinery in the intestine: the plant polyphenol caseThe structural biology of oestrogen metabolismA systems biology approach reveals the role of a novel methyltransferase in response to chemical stress and lipid homeostasis.Structure and Protein-Protein Interactions of Human UDP-GlucuronosyltransferasesSulforaphane Protects against Cardiovascular Disease via Nrf2 ActivationEmerging roles of Nrf2 and phase II antioxidant enzymes in neuroprotectionXenobiotic Metabolism and Gut MicrobiomesPROXIMAL: a method for Prediction of Xenobiotic MetabolismNecrosis, and then stress induced necrosis-like cell death, but not apoptosis, should be the preferred cell death mode for chemotherapy: clearance of a few misconceptionsDetoxification and stress response genes expressed in a western North American bumble bee, Bombus huntii (Hymenoptera: Apidae).Overexpression of a cytochrome P450 and a UDP-glycosyltransferase is associated with imidacloprid resistance in the Colorado potato beetle, Leptinotarsa decemlineata.Effects of resveratrol on drug- and carcinogen-metabolizing enzymes, implications for cancer prevention.Dopamine D1 receptor activation induces dehydroepiandrosterone sulfotransferase (SULT2A1) in HepG2 cellsNRF2 activation restores disease related metabolic deficiencies in olfactory neurosphere-derived cells from patients with sporadic Parkinson's diseaseThe retinoblastoma tumor suppressor regulates a xenobiotic detoxification pathway.In Silico Prediction of Human Sulfotransferase 1E1 Activity Guided by Pharmacophores from Molecular Dynamics Simulations.Three-dimensional quantitative structure-activity relationship studies on UGT1A9-mediated 3-O-glucuronidation of natural flavonols using a pharmacophore-based comparative molecular field analysis model.Diminution of hepatic response to 7, 12-dimethylbenz(α)anthracene by ethyl acetate fraction of Acacia catechu willd. through modulation of xenobiotic and anti-oxidative enzymes in rats.Modulation of Metabolic Detoxification Pathways Using Foods and Food-Derived Components: A Scientific Review with Clinical ApplicationResistance to cancer chemotherapy: failure in drug response from ADME to P-gp.Noscapine recirculates enterohepatically and induces self-clearance.From omics to drug metabolism and high content screen of natural product in zebrafish: a new model for discovery of neuroactive compound.Recent advances in sulfotransferase enzyme activity assays.Tolfenamic acid suppresses cytochrome P450 2E1 expression in mouse liverDrug-Drug Interactions Potential of Icariin and Its Intestinal Metabolites via Inhibition of Intestinal UDP-Glucuronosyltransferases.The pregnane X receptor in tuberculosis therapeutics.Regulation of Hepatic Drug-Metabolizing Enzymes in Germ-Free Mice by Conventionalization and ProbioticsAltered UDP-glucuronosyltransferase and sulfotransferase expression and function during progressive stages of human nonalcoholic fatty liver disease.RNA-sequencing quantification of hepatic ontogeny and tissue distribution of mRNAs of phase II enzymes in mice.Drug metabolism alterations in nonalcoholic fatty liver diseaseCharacterizing drug-metabolizing enzymes and transporters that are bona fide CAR-target genes in mouse intestineApoptosis and necrosis in the liverGenotypes Affecting the Pharmacokinetics of Anticancer Drugs.Distribution of genetic polymorphisms of genes encoding drug metabolizing enzymes & drug transporters - a review with Indian perspective.
P2860
Q26739975-30E468BF-D21F-4CAD-A4BF-E45DF471D6C2Q26747249-A3364A2D-F28B-452E-87D9-3B1D6A910D8BQ26764913-A759E710-B276-43C1-A7F4-5EF8C236B599Q26787099-650FB5B7-822E-4CEB-8C72-D3E679C9FE7EQ26799149-B1D39594-610C-41B3-A921-5084D49119A1Q26997383-CE4D6502-391E-4229-AD9B-74F1891052B1Q27000798-E49BECBD-C573-4C27-A42D-F1369E1283A1Q27009283-AC5F2275-F37F-4059-B101-27D2A845D08BQ27931165-AA3938F6-6619-4160-8246-BB9C9C57E707Q28071266-C8074BDB-A06B-4944-BDFB-00DBF22CCE9EQ28393421-37176C62-BEB4-417F-8E1E-E668C7267F2DQ28396785-00D0C007-5601-490F-B21B-1B5954603306Q28554445-AE7020AE-5DFA-44FF-9E8F-77CFCCC9DE89Q28603730-581FEE7C-1EB9-4F3B-BDF5-4E67ABAEB992Q28652643-63828F61-DAD2-40A0-A927-0975B269F80DQ30561386-E0121390-A5D8-43B0-8156-18A8920C6F7CQ33687397-369B2E06-0BBE-4BD4-BCC3-CBF838800612Q33771427-686072C2-A2C7-4F38-8DC4-E79BD50E4ACAQ33869687-E2E40CE5-31C8-4F1B-831A-A686DE45DE8CQ33958143-20E5FB90-BA18-46E2-B859-18F240226514Q34055895-C19D9A4F-EB48-44A6-9C11-3ED2D6504E79Q34500763-3D48C6B0-4CCB-4487-AC85-760F1E4B0AE0Q34552084-BD02454C-396E-4381-8EEB-A6DDE8C0C071Q35108644-F6B8FFB8-02B7-4BDC-97AE-98C723040C12Q35806779-DF037A19-4918-43D5-ADC3-698BF174264EQ35852614-B7F548E3-1742-47D5-8B67-CA9954219B26Q35893886-33A1E6FE-7576-4356-8961-FC6F63BE9F44Q36167799-D5DE0E63-CBCD-4720-9459-0C2553E6B8B3Q36182302-15E13E08-2F32-4FED-A57D-170344B43281Q36217454-D34B5131-1CF4-4588-B873-7BB2EC47A66CQ36344087-C94FAF85-5383-4A56-9F59-86768C11626BQ36451492-6103FCB0-3A0B-4674-AFED-B7E4E11F635BQ36559646-959F4CF5-78BB-4143-B324-AC090569E3FCQ36642354-DECD069F-7661-41AA-9773-486844475966Q36717163-73C4EC3A-4699-4144-98E2-9361ADD28EE6Q37120909-9142C111-8140-44CB-9D2F-7608A1C9C47CQ37302210-F8840501-39F5-46C8-8784-B0EAC33C9B32Q37403072-0596113A-7BFE-4E82-9334-401E300247A2Q37685527-91F0D046-5B7B-4B3F-82DD-1A28BCEC9827Q37715233-E482FF8D-1C1C-4D95-A4A4-38343EA063F8
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Phase II drug metabolizing enzymes.
@en
Phase II drug metabolizing enzymes.
@nl
type
label
Phase II drug metabolizing enzymes.
@en
Phase II drug metabolizing enzymes.
@nl
prefLabel
Phase II drug metabolizing enzymes.
@en
Phase II drug metabolizing enzymes.
@nl
P1476
Phase II drug metabolizing enzymes.
@en
P2093
Petra Jancova
P304
P577
2010-06-01T00:00:00Z